Clinuvel Pharmaceuticals Reports Positive Results From Adolescent Patient Study for Genetic Disorder Drug Candidate

MT Newswires Live02-10

Clinuvel Pharmaceuticals (ASX:CUV) reported positive results from a post-authorization study of its Scenesse drug candidate in adolescent erythropoietic protoporphyria patients, according to a Monday Australian bourse filing.

Erythropoietic protoporphyria is a hereditary disorder characterized by skin sensitivity to sunlight and some artificial light.

Preliminary results from the study in adult and adolescent patients showed that the drug candidate was well tolerated by all patients enrolled in the study, with the safety profile consistent with that reported in long-term adult use.

The controlled-release profile of the Scenesse implant in adolescent patients was similar to that observed in earlier studies in adults.

A total of 28 patients were assessed, including 14 adults and 14 adolescents, with ages ranging between 12 years and 17 years, the filing said. It added that all eligible enrolled patients elected to receive further treatment in 2024 or this year.

Data from the study will be included in a regulatory package the firm is planning to submit in support the expansion of the Scenesse indication to include treatment of adolescent patients.

The company's shares fell nearly 1% in early trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2510074259?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-10 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510074259","market":"sg","top_or_hot":-1,"title":"Clinuvel Pharmaceuticals Reports Positive Results From Adolescent Patient Study for Genetic Disorder Drug Candidate","media":"MT Newswires Live","content":"<html><body><p> Clinuvel Pharmaceuticals (ASX:CUV) reported positive results from a post-authorization study of its Scenesse drug candidate in adolescent erythropoietic protoporphyria patients, according to a Monday Australian bourse filing.</p><p>Erythropoietic protoporphyria is a hereditary disorder characterized by skin sensitivity to sunlight and some artificial light.</p><p>Preliminary results from the study in adult and adolescent patients showed that the drug candidate was well tolerated by all patients enrolled in the study, with the safety profile consistent with that reported in long-term adult use.</p><p>The controlled-release profile of the Scenesse implant in adolescent patients was similar to that observed in earlier studies in adults.</p><p>A total of 28 patients were assessed, including 14 adults and 14 adolescents, with ages ranging between 12 years and 17 years, the filing said. It added that all eligible enrolled patients elected to receive further treatment in 2024 or this year.</p><p>Data from the study will be included in a regulatory package the firm is planning to submit in support the expansion of the Scenesse indication to include treatment of adolescent patients.</p><p>The company's shares fell nearly 1% in early trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Pharmaceuticals Reports Positive Results From Adolescent Patient Study for Genetic Disorder Drug Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Pharmaceuticals Reports Positive Results From Adolescent Patient Study for Genetic Disorder Drug Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-10 09:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Clinuvel Pharmaceuticals (ASX:CUV) reported positive results from a post-authorization study of its Scenesse drug candidate in adolescent erythropoietic protoporphyria patients, according to a Monday Australian bourse filing.</p><p>Erythropoietic protoporphyria is a hereditary disorder characterized by skin sensitivity to sunlight and some artificial light.</p><p>Preliminary results from the study in adult and adolescent patients showed that the drug candidate was well tolerated by all patients enrolled in the study, with the safety profile consistent with that reported in long-term adult use.</p><p>The controlled-release profile of the Scenesse implant in adolescent patients was similar to that observed in earlier studies in adults.</p><p>A total of 28 patients were assessed, including 14 adults and 14 adolescents, with ages ranging between 12 years and 17 years, the filing said. It added that all eligible enrolled patients elected to receive further treatment in 2024 or this year.</p><p>Data from the study will be included in a regulatory package the firm is planning to submit in support the expansion of the Scenesse indication to include treatment of adolescent patients.</p><p>The company's shares fell nearly 1% in early trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510074259","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510074259","pubTimestamp":1739150791,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals (ASX:CUV) reported positive results from a post-authorization study of its Scenesse drug candidate in adolescent erythropoietic protoporphyria patients, according to a Monday ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Clinuvel Pharmaceuticals报告遗传疾病候选药物青少年患者研究的积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":0.9,"GENE":1},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) reported positive results from a post-authorization study of its Scenesse drug candidate in adolescent erythropoietic protoporphyria patients, according to a Monday Australian bourse filing.Erythropoietic protoporphyria is a hereditary disorder characterized by skin sensitivity to sunlight and some artificial light.Preliminary results from the study in adult and adolescent patients showed that the drug candidate was well tolerated by all patients enrolled in the study, with the safety profile consistent with that reported in long-term adult use.The controlled-release profile of the Scenesse implant in adolescent patients was similar to that observed in earlier studies in adults.A total of 28 patients were assessed, including 14 adults and 14 adolescents, with ages ranging between 12 years and 17 years, the filing said. It added that all eligible enrolled patients elected to receive further treatment in 2024 or this year.Data from the study will be included in a regulatory package the firm is planning to submit in support the expansion of the Scenesse indication to include treatment of adolescent patients.The company's shares fell nearly 1% in early trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.3","shortVersion":"4.32.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2510074259"}